Prolonged angiotensin-(1-7) infusion inhibits hepatic fibrosis in rats with bile duct ligation.
- Author:
Xu LI
1
;
Zuowei NING
;
Wei LUO
;
Wenyong ZHANG
;
Changhui YU
Author Information
- Publication Type:Journal Article
- MeSH: Angiotensin I; administration & dosage; pharmacology; Animals; Bile Ducts; surgery; Infusions, Parenteral; Ligation; Liver Cirrhosis, Experimental; metabolism; prevention & control; surgery; Male; Peptide Fragments; administration & dosage; pharmacology; Rats; Rats, Wistar
- From: Journal of Southern Medical University 2012;32(7):944-947
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the inhibitory effect of angiotensin-(1-7) on liver fibrosis induced by bile duct ligation in rats.
METHODSEighteen Wistar rats were randomized into 3 groups and subject to sham operation, bile duct ligation (BDL), or BDL with angiotensin-(1-7) treatment. An osmotic minipump was implanted intraperitoneally for administration of saline in the sham-operated and BDL groups and angiotensin-(1-7) (25 µg·kg(-1)·h(-1)) in angiotensin-(1-7) treatment group. After a 4-week treatments, the fibrosis score, Masson staining, and hydroxyproline assay were used to evaluate the level of liver fibrosis in the rats, and immunohistochemistry was used to detect expression of α-smooth muscle actin (α-SMA) in the liver tissue.
RESULTSCompared with BDL group, a 4-week treatment with angiotensin-(1-7) following BDL significantly reduced the fibrosis score (2.33±0.52 vs 5.17±0.75), hydroxyproline content (0.36±0.03 vs 0.52±0.04) and α-SMA expression (54.11±17.55 vs 191.84±31.72) in the liver tissue of the rats (P<0.01).
CONCLUSIONProlonged infusion of angiotensin-(1-7) inhibit the formation of hepatic fibrosis in rats following bile duct ligation.
